Last updated on May 2019

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke


Brief description of study

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Clinical Study Identifier: NCT02586233

Find a site near you

Start Over

Henry Ford Health System

Detroit, MI United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

UC Health Memorial Hospital

Colorado Springs, CO United States
  Connect »

Houston Methodist

Houston, TX United States
  Connect »

OSU - Wexner Medical Center

Columbus, OH United States
  Connect »

Monash Health

Clayton, Australia
  Connect »

University of Louisville

Louisville, KY United States
  Connect »

CHU Gabriel Montpied

Clermont-Ferrand, France
  Connect »

Charing Cross Hospital

London, United Kingdom
  Connect »

Salford Royal Hospital

Salford, United Kingdom
  Connect »

Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom
  Connect »

NsP Spisska Nova Ves

Spišská Nová Ves, Slovakia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.